TABUK PHARMACEUTICALS TO ADD NEW THERAPEUTIC CATEGORY TO PORTFOLIO THROUGH AN EXCLUSIVE DISTRIBUTION AGREEMENT WITH GENETIC SPA
Tabuk Pharmaceutical Manufacturing Company (“Tabuk”), one of the leading pharmaceutical companies in the Middle East and North Africa region (MENA) region, has entered into an exclusive distribution agreement with the Italian drug maker Genetic SpA.
Under the terms of this distribution agreement, Tabuk will have exclusive rights to market and sell Genetic’s highly innovative ophthalmic range of products in Saudi Arabia. This project demonstrates Tabuk’s continued commitment to patients and to offering New medicines in Saudi Arabia within an ongoing collaboration with Global partners to make these new hig quality products to patients .
“Ophthalmics can become a complementary addition to our therapeutic pipeline and will add more diversity to our drug discovery and development approaches” commented Dr. Rana Azzam, Tabuk’s Senior VP of Business Development. , “I am very pleased by this collaboration and the future business we will build together, we look forward to continuing to expand our portfolio and better serving patients' needs.”
The combination of these assets with Tabuk’s existing platform will significantly strengthen Tabuk’s position as a leading generic company in KSA and the MENA region.